Providing a pathway to potent pain therapy without the risk of addiction and serious side effects.
Phoenix is a pre-clinical pharmaceutical company driven by a mission to bring potent, safe pain therapies to market without risk of abuse and addiction.
Our lead candidate for acute & chronic pain: PPL- 138, represents a novel new class of analgesics with robust preclinical validation of potent pain relief (100X potency of morphine), low risk of abuse/addiction, and no respiratory depression.
Our second drug candidate PPL-103, offers promising potential for the treatment of addiction, as well for pain. It has also demonstrated low risk of abuse/addiction and reduced opioid side effects.
We are advancing PPL-138 into Phase I human clinical trials in 2022-2023, to be followed by PPL-103.
More than $8M has been raised to date through two seed rounds and grants from the U.S. Army and NIH/NIDA, as well as substantial investments-in-kind.
Both compounds have promising potential to capture a sizable portion of the $30B opioid therapeutics market.
Opioids are the most widely prescribed drugs for treatment of moderate to severe pain. They are also the most powerful analgesics for treatment of acute and chronic pain. However, their use is plagued by serious side effects, including abuse and addiction, severe withdrawal, constipation, respiratory depression, and death from overdose.
Millions of Americans are seriously addicted to opioids – and it is a devastating addiction. There is an immense unmet medical need to comprehensively address the abuse, addiction and mortality associated with opiates.
PPL has a portfolio of drugs under development with unique opioid receptor characteristics that do not produce the euphoric “high” that leads to abuse and addiction, while still treating moderate to severe acute and chronic pain without the dangerous side effects found in other opioids such as morphine, OxycodoneTM, HydrocodoneTM, etc.
We continue to seek complimentary business and investment relationships, out-licensing opportunities and/or co-development opportunities with both domestic and overseas partners as we advance our drug candidates through pre-clinical and clinical trials.